Foghorn therapeutics general counsel
WebA New Class of Therapeutics. Foghorn is pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression. These precision therapeutic candidates target disease … WebAug 23, 2024 · CAMBRIDGE, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene...
Foghorn therapeutics general counsel
Did you know?
WebApr 10, 2024 · The genetic tuning innovator adds pioneering genetic medicine expert and an accomplished biotechnology lawyer to its management team.. DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Today, leading epigenomic editing company Tune Therapeutics introduced two members to its leadership team: Chief Scientific Officer, Derek Jantz, … WebPrior to that, Mike was the senior vice president, general counsel and secretary of Vertex Pharmaceuticals, where he led its global legal function, supported numerous business development initiatives, and enhanced corporate governance for the company as it …
WebApr 10, 2024 · Before Rackspace, Bross served as Senior Vice President and General Counsel for Datapipe for over ten years. Before Datapipe, Bross was the founder and Managing Partner of Bross Cummings Pereira & Moore, a full-service law firm representing high-tech, telecommunications, and public-sector corporate clients. ... Foghorn … WebMar 9, 2024 · CAMBRIDGE, Mass., March 09, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. FHTX, ... General and administrative expenses were $30.7 million for the year ended December 31, 2024, compared to ...
WebFind the latest Foghorn Therapeutics Inc. (FHTX) stock quote, history, news and other vital information to help you with your stock trading and investing. WebJul 8, 2024 · FOGHORN THERAPEUTICS INC. (Name of Registrant as Specified In Its Charter) ... Prior to joining Foghorn, Mr. LaCascia served as Senior Vice President and General Counsel from May 2024 to April 2024 and Chief Legal Officer from April 2024 through October 2024 of Q-State BioSciences, Inc. From January 2014 through October …
WebFoghorn Therapeutics is a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene …
WebFoghorn Therapeutics, Inc May 2024 - Present1 year 5 months Cambridge, Massachusetts, United States Associate, Mergers & Acquisitions Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates Oct... css acceptWebThe average salary for Associate General Counsel at companies like FOGHORN THERAPEUTICS INC in the United States is $233,472 as of February 27, 2024, but the … cssa chartering \u0026 shipping services saWebFogPharma 6,058 followers 2w Here at Fog, our team of visionaries is inventing the future of precision medicines, and their remarkable work does not go unnoticed. We're thrilled to announce the... css accepting profileWebFoghorn is pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression. These precision therapeutic candidates target disease dependencies within the chromatin regulatory … css acleWebNov 12, 2024 · CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and … cssa cherokeeWebMar 9, 2024 · CAMBRIDGE, Mass., March 09, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), ... General and administrative expenses were $30.7 million for the year ended December 31, 2024, compared to $21.7 million for the year ended December 31, 2024. This increase was primarily due to an increase in investments to … earbud repair shops near meWebNov 12, 2024 · CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Michael LaCascia as … css access element by id